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Abstract 
Background: A wide range of preventive medications for mi-
graine attacks, with varying efficacy is currently in use. Studies 
comparing the efficacies of these drugs would be of value in the 
proper treatment of the disease. The present study compared the 
frequency, duration and intensity of migraine attacks during and 
following treatment with cyproheptadine (4 mg, twice daily) or 
Blellergal (belladonna 0.1 mg, ergotamine 0.3 mg and pheno-
barbital 20 mg). 
 
Methods: 118 patients 15 to 45 year-old with migraine head-
aches were randomly allocated to groups I (n=36), II (n=40) 
and III (n=42) and treated during three consecutive phases of 
45 days. In phase one all groups received two oral placebo 
tablets daily. In phase two, group I continued with placebo, 
groups II and III received cyproheptadine (4 mg, twice daily) 
and Bellergal (three tablets daily), and finally, in phase three 
all groups were treated with placebo, respectively.  
 
Results: Cyproheptadine and Bellergal treatments signifi-
cantly reduced the frequency, duration and intensity of mi-
graine attacks. These parameters remained low during phase 
three (placebo) in cyproheptadine treated patients as compared 
to those who only received placebo. But there was a rebound 
effect following discontinuation of Bellergal.  
 
Conclusion: Cyproheptadine and Bellergal seem to preven-
tive migraine attacks. Cyproheptadine is a preferred choice 
because its effects were partially preserved following with-
drawal. 
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Introduction 
igraine is a chronic condition of recurring headaches 
of moderate to severe intensity, affecting 6% of men, 
18% of women and may last for part of a day or as 
long as few days.1,2 The prevention of migraine headaches by 
drug therapy is acute or chronic and both approaches are often 
required in patients who experience frequent severe head-
aches.3 Indications for migraine prevention therapy include two 
or more attacks per month which procure disability.3 
A wide range of preventive treatments with varying efficacy 
is currently in use and the range of these drugs is expanding. 
Alpha2 agonists, anticonvulsants, antidepressants, beta-
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blockers, calcium-channel blockers and non-
steroidal anti-inflammatory drugs, etc, are 
used for preventive therapy.3,4 Cyprohep-
tadine is a serotonin antagonist, which is rec-
ognized as clinically effective in prevention of 
migraine attacks.5 
This study was undertaken to compare the ef-
fects of cyproheptadine and Bellergal (including 
ergotamine, belladonna alkaloids and pheno-
barbital) on the frequency, duration and the in-
tensity of migraine attacks. Since the curative 
effects of these drugs are not clear, the fre-
quency, duration and the intensity of migraine 
attacks before drug usage and after withdrawal 
were also compared. 
 
Patients and Methods 
 
This work was approved by the Research Ethi-
cal Committee of Shahrekord University of 
Medical Sciences. Proper information regard-
ing the use of medications was provided to the 
patients and an informed consent was ob-
tained. 118 patients with migraine headache 
(ages ranging from 15 to 45 years) randomly 
selected from the author's neurology private 
clinic (Shahrekord, Iran). Eligible patients had 
to meet the diagnostic criteria for migraine as 
defined by the International Headache Society 
(HIS).6 Accordingly, a patient must have at 
least five headache attacks lasting for 4-74 hrs 
with at least two of the following symptoms; 
lateralized headache, pulsating pain of moder-
ate to high intensity, exacerbation by effortful 
physical activity, nausea and/or vomiting, 
photo- and phono-phobia.6 
A minimal duration of the disorder had to be 
one year and at least two attacks had to take 
place one month before participating in the 
study. Exclusion criteria included those patients 
with secondary headache, neurological disor-
ders, last two months trials of medication for 
prophylaxis of migraine, severe medical or psy-
chiatric illness, and use of hormonal contracep-
tives, pregnancy, analgesic usage for other ill-
nesses, or drug abuse. Patients unable to com-
plete a headache diary or to differentiate vari-
ous headache types were also excluded. 
 
Patients and Methods 
 
Throughout the study, the patients and the in-
vestigator were blind to the administered 
medications. Cyproheptadine (4 mg, twice 
daily) and Bellergal tablets (0.1 mg belladonna, 
0.3 mg ergotamine and 20 mg phenobarbi-
tal/tablet) were used to prevent migraine at-
tacks obtained from Darupakhsh and Sobhan 
Companies, Tehran, Iran. Tablets (both drugs 
and placebo) were put into identical packets 
and randomly coded 1, 2 or 3 by a pharmacist 
without knowing the content. Tablets were pre-
scribed by the neurologist through code num-
bers up to the end of the study. 
Patients were randomly allocated into three 
groups and treated in three consecutive 
phases, each lasting 45 days. During phase 
one, patients of all groups received two pla-
cebo tablets daily. During phase two which 
started at day 46 and ended at day 90, group I 
continued with placebo (n=36), group II (n=40) 
received two cyproheptadine tablets daily (8 
mg/day), and group III (n=42) received three 
Bellergal tablets daily. As washout period, 
starting at day 91, all patients stopped medica-
tion for eight days. Phase three started at day 
99, after washout period, and again all patients 
received placebo medication until day 144. 
During the course of the study patients were 
free to take one or two tablets of acetamino-
phen-codeine when needed. 
Patients had a diagnostic headache diary to 
record their headache symptoms, such as the 
type, the frequency, duration and the intensity. 
They were also asked to record and report to the 
physician in charge of the study the intensity of 
their headache on an arbitrary scale (10 scale 
point) with one reflecting the least intensity (ab-
sence of effect on daily activity), and 10 reflecting 
the most intensity (preventing daily activity). 
 
Statistical analysis 
Data are presented as mean±SD. Analysis 
of the data involved one- way analysis of vari-
ance (ANOVA), Tukey’s HSD, Kruskal-Wallis 
and multiple comparison tests.  
 
Results 
 
The mean±SD ages of patients participated in 
groups I, II and III were 29.7±8.1 yrs, 29.2±7.8 
yrs and 31.9±8.4 yrs, respectively and were not 
statistically different. Before participating in the 
study, 83.1% of patients had migraine without 
aura and 16.9% with aura with the frequency 
and duration of migraine headaches of 
4±1.8/month and 23.1±10.9 hrs respectively. 
Tables 1, 2 and 3 show the values of frequen-
cies, durations and intensities of migraine at-
tacks during placebo treatments in group l dur-
Table 1: Effects of placebo treatments (phase 1, 2 and 3) 
on the frequency (FR; attacks/month), duration (DU; hrs) 
and intensity (IN; 1-10) of migraine attacks of group I. 
Phase FR  DU IN 
1 (Placebo) 3.51+2.32 21+8.60 7.21+2.05 
2 (Placebo) 4.80+2.03 26.4+8.98 7.34+2.86 
3 (Placebo) 3.94+1.36 23.5+7.90 8.02+1,83 
Data are presented as mean±SD. 
p>0.05 when three phases compared. 
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ing all three phases and in groups II and III dur-
ing phase 1. The values of these parameters 
were not statistically different from each other, 
where as these parameters decreased signifi-
cantly during cyproheptadine treatment (p<0.05; 
Table 2). Following drug withdrawal (phase 3), 
the frequency, duration and intensity of attacks 
in group II (cyproheptadine) did not change sig-
nificantly (Table 2). In group III these parame-
ters decreased significantly during Bellergal 
treatment (p<0.05; Table 3) but returned back to 
the pretreated levels after withdrawal (Table 3). 
Comparison of the results of groups II and III 
revealed that only the reduction duration of mi-
graine attacks in cyproheptadine treated group 
(table 2) was more pronounced than of Beller-
gal group (P<0.05, Table 3). 
 
Discussion 
 
The causes of migraine headaches and the 
mechanisms of action of antimigrane drugs are 
not fully understood. However, there are clini-
cal and experimental evidences indicating that 
extracerebral arterial vasodilation, extradural 
neurogenic inflammation, and decreased inhi-
bition of central pain transmission are involved 
in the pathogenesis of the migraine head-
ache.8 Serotonin is one of the known neuro-
transmitters that participate in the above men-
tioned processes. Therefore, cyproheptadine, 
which is a competitive serotonin receptor 
blocking agent, might exert its antimigraine 
effects by blocking antiserotonergic serotonin 
receptors.9 Its antihistamine and anticholiner-
gic activity may also potentate the anti-
migraine activity of this drug.9 
The frequency, duration and intensity of 
migraine attacks were reduced by both cypro-
heptadine and Bellergal (Tables 2 and 3). The 
prophylactic effects of cyproheptadine on mi-
graine attacks are well established,7 whereas 
the efficacy of Bellergal  is in question.3 This 
study demonstrated that cyproheptadine might 
be a suitable antimigraine medication for pre-
venting migraine attacks, or at least might be 
suitable alternative for patients who can not 
tolerate other antimigraine drugs. 
Little evidence exists about the prophylactic 
effects of ergotamine alone, or in combination 
with belladonna alkaloids and phenobarbital, 
on migraine attacks but its abortive effects of is 
indisputable.8 However, a rebound effect was 
observed following cessation of Bellergal us-
age. The reduction in frequency, duration, or 
intensity of attacks in phase three, in cypro-
heptadine group may be considered as "free-
attack effect", a phenomenon which occurs 
following prevention of attacks in epilepsy. 
However, there was statistically no difference 
between phase three and phase one, in Bel-
lergal group. It means, reduction of migraine 
attack, following an attack-free period, is not 
general and is specific for cyproheptadine, in 
this study. This specific effect is not clear for 
other drugs, and needs more investigations. 
The mechanism involved in this phenomenon, 
in cyproheptadine effect is not known. Sero-
tonin is a neurotransmitter, which seems to be 
largely involved in pathogenesis of migraine 
headache8. Cyproheptadine is a serotonin an-
tagonist. Therefore, inhibition of serotonin re-
ceptors, by cyproheptadine, might have 
caused a change in serotonin receptor quantity 
or quality (sensitivity). This phenomenon 
needs also more investigations.  
Both medications demonstrated high anti-
cholinergic and sedative activity. However, in 
global the side effects of cyproheptadine were 
less than Bellergal. Therefore, cyproheptadine 
due to higher efficacy as a preventive therapy, 
preservation of effectiveness following discon-
tinuation, and less side effects seems to be 
preferred medication compared to Bellergal for 
prevention of migraine attacks. It should be 
noted that the choice of the preventives to pre-
scribe should be based on the patient's physi-
cal and mental conditions, too. For example, a 
patient subject to low weight would be more 
suitable for cyproheptadine and a patient sub-
ject to down moods and insomnia would be 
more suitable for amitriptyline. 
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